Bioorganic Chemistry 87 (2019) 773-782

Contents lists available at ScienceDirect

Bioorganic Chemistry
Journal homepage: www.elsevier.com/locate/bioorg

Probing the antibacterial and anticancer potential of tryptamine based mixed

ligand Schiff base Ruthenium(III) complexes
Manzoor Ahmad Malika, Md Kausar Razab, Ovas Ahmad Dara, Athar Adil Hashmia,*
a
Bioorganic Lab., Department of Chemistry, Jamia Millia Islamia, New Delhi 110025, India

ARTICLE INFO ABSTRACT

______________________ ____________________________________________________________

Anticancer Cancer is one of the most important health problems and is a leading cause
of death worldwide. For the treatment of cancer chemotherapy is an
Ruthenium important modality. Pt(II) coordination complexes namely cisplatin,
carboplatin and oxaliplatin have become the first line of anticancer drugs.
Coordination Complexes Although Platinum based anticancer drugs are highly efficient but their
use is limited by severe side effects and acquired drug resistance.

1. Introduction
Pt(II) coordination complexes namely cisplatin, drugs. Pt(II) coordination complexes namely
carboplatin and oxaliplatin have become the first line cisplatin, carboplatin and oxaliplatin have become the
of anticancer drugs. Pt(II) coordination complexes first line of anticancer drugs.
namely cisplatin, carboplatin and oxaliplatin have
become the first line of anticancer drugs. Pt(II)
coordination complexes namely cisplatin, carboplatin
and oxaliplatin have become the first line of
anticancer drugs. Pt(II) coordination complexes
namely cisplatin, carboplatin and oxaliplatin have
become the first line of anticancer drugs. Pt(II)
coordination complexes namely cisplatin, carboplatin
and oxaliplatin have become the first line of
anticancer drugs. coordination complexes namely
cisplatin, carboplatin and oxaliplatin have become the
first line of anticancer drugs. Pt(II) coordination
complexes namely cisplatin, carboplatin and
oxaliplatin have become the first line of anticancer

* Corresponding authors
http://doi/10.1016/j.org.2019.03.080